Outlook Therapeutics Inc (OTLK)
7.95
+0.62
(+8.46%)
USD |
NASDAQ |
May 20, 16:00
7.95
0.00 (0.00%)
After-Hours: 17:10
Outlook Therapeutics Net Income (TTM): -159.13M for March 31, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -159.13M |
| December 31, 2023 | -51.50M |
| September 30, 2023 | -58.98M |
| June 30, 2023 | -60.34M |
| March 31, 2023 | -57.20M |
| December 31, 2022 | -70.25M |
| September 30, 2022 | -66.05M |
| June 30, 2022 | -65.11M |
| March 31, 2022 | -59.77M |
| December 31, 2021 | -53.17M |
| September 30, 2021 | -53.16M |
| June 30, 2021 | -49.68M |
| March 31, 2021 | -40.50M |
| December 31, 2020 | -33.09M |
| September 30, 2020 | -35.24M |
| June 30, 2020 | -35.41M |
| March 31, 2020 | -36.84M |
| December 31, 2019 | -41.38M |
| Date | Value |
|---|---|
| September 30, 2019 | -34.52M |
| June 30, 2019 | -36.63M |
| March 31, 2019 | -40.62M |
| December 31, 2018 | -37.91M |
| September 30, 2018 | -30.09M |
| June 30, 2018 | -24.27M |
| March 31, 2018 | -21.17M |
| December 31, 2017 | -21.67M |
| September 30, 2017 | -38.85M |
| June 30, 2017 | -43.07M |
| March 31, 2017 | -60.07M |
| December 31, 2016 | -55.56M |
| September 30, 2016 | -53.33M |
| June 30, 2016 | -59.90M |
| March 31, 2016 | -48.91M |
| December 31, 2015 | -59.35M |
| September 30, 2015 | -47.39M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-159.13M
Minimum
Mar 2024
-33.09M
Maximum
Dec 2020
-54.90M
Average
-52.33M
Median
Net Income (TTM) Benchmarks
| Cutera Inc | -157.56M |
| Actinium Pharmaceuticals Inc | -46.45M |
| GT Biopharma Inc | -7.597M |
| Karyopharm Therapeutics Inc | -146.34M |
| Marinus Pharmaceuticals Inc | -145.34M |